SEVEN, TEN OR THIRTEEN? THE COST-UTILITY OF INFANT VACCINATION WITH A 7-, 10-OR 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN THE NETHERLANDS

被引：3
|
作者：
Vemer, P. [1 ]
de Greeff, S. C. D. [2 ]
Schouls, L. M. [2 ]
Al, M. J. [1 ]
de Melker, H. D. [2 ]
机构：
[1] Erasmus MC, Rotterdam, Netherlands
[2] Natl Inst Publ Hlth & Environm, RIVM, NL-3720 BA Bilthoven, Netherlands
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74112-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A228 / A228
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
    Perdrizet, Johnna
    Santana, Carlos Felipe S.
    Senna, Thais
    Alexandre, Rodrigo Fernandes
    de Almeida, Rodrigo Sini
    Spinardi, Julia
    Wasserman, Matt
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (04) : 1162 - 1172
  • [32] Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China
    Mo, Xiuting
    Tobe, Ruoyan Gai
    Liu, Xiaoyan
    Mori, Rintaro
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (11) : E353 - E361
  • [33] COST-EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS IN PORTUGAL
    Alarcao, J.
    Fiorentino, F.
    Gouveia, M.
    Jesus, G.
    Costa, J.
    Borges, M.
    VALUE IN HEALTH, 2016, 19 (07) : A414 - A414
  • [34] Pneumococcal Meningitis Vaccine Breakthroughs and Failures After Routine 7-Valent and 13-Valent Pneumococcal Conjugate Vaccination in Children in France
    Godot, Cecile
    Levy, Corinne
    Varon, Emmanuelle
    Picard, Capucine
    Madhi, Fouad
    Cohen, Robert
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (10) : E260 - E263
  • [35] Compared effectiveness of the 7-valent pneumococcal conjugate vaccine in children with the 13-valent vaccine in adults
    Gaillat, J.
    MEDECINE ET MALADIES INFECTIEUSES, 2013, 43 (06): : 215 - 221
  • [36] COST-EFFECTIVENESS OF PAEDIATRIC PNEUMOCOCCAL VACCINATION IN THE NETHERLANDS; AN UPDATE FOR THE 7-VALENT AND FORECAST FOR THE 10-AND 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINES (PCVS)
    Rozenbaum, M.
    Sanders, E. A.
    van Hoek, A.
    Jansen, A. G.
    van de Ende, A.
    Rodenburg, G.
    van den Dobbelsteen, G.
    Hak, E.
    Postma, M. J.
    VALUE IN HEALTH, 2009, 12 (07) : A294 - A294
  • [37] Cost-Effectiveness of a 10-Versus 13-Valent Pneumococcal Conjugate Vaccine in Denmark and Sweden
    Klok, Rogier M.
    Lindkvist, Rose-Marie
    Ekelund, Mats
    Farkouh, Raymond A.
    Strutton, David R.
    CLINICAL THERAPEUTICS, 2013, 35 (02) : 119 - 134
  • [38] Vaccination status and immune response to 13-valent pneumococcal conjugate vaccine in asplenic individuals
    Nived, Per
    Jorgensen, Charlotte Svaerke
    Settergren, Bo
    VACCINE, 2015, 33 (14) : 1688 - 1694
  • [39] Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China
    Shen, Kunling
    Wasserman, Matthew
    Liu, Dongdong
    Yang, Yong-Hong
    Yang, Junfeng
    Guzauskas, Greg F.
    Wang, Bruce C. M.
    Hilton, Betsy
    Farkouh, Raymond
    PLOS ONE, 2018, 13 (07):
  • [40] Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada
    Wilson, Michele
    Wasserman, Matt
    Jadavi, Taj
    Postma, Maarten
    Breton, Marie-Claude
    Peloquin, Francois
    Earnshaw, Stephanie
    McDade, Cheryl
    Sings, Heather
    Farkouh, Raymond
    INFECTIOUS DISEASES AND THERAPY, 2018, 7 (03) : 353 - 371
12345